Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials DOI Creative Commons

Jinlv Qin,

Guizuo Wang,

Dong Han

et al.

Global Heart, Journal Year: 2023, Volume and Issue: 18(1), P. 58 - 58

Published: Oct. 26, 2023

Background: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). Methods: A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment PH macitentan, compared placebo or blank, were reviewed. Studies pooled weighted mean differences (WMDs) risk ratios (RRs), 95% confidence intervals (CIs). Results: Six RCTs (enrolling 1,003 participants) met inclusion criteria. Macitentan showed significant effects 6-min walk distance (6MWD) (WMD 12.06 m, CI 2.12 21.99 m), vascular resistance (PVR) –186.51 dyn·s/cm–5, –232.72 –140.29 dyn·s/cm–5), artery pressure (mPAP) –3.20 mmHg, –5.93 –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) –232.47 ng/L, wCI –318.22 –146.72 ng/L), cardiac index 0.39 L/min/m2, 0.20 0.58 L/min/m2). Conclusion: significantly improved 6MWD, PVR, mPAP, NT-proBNP, PH. should be further validated

Language: Английский

Benefits of melatonin on mortality in severe-to-critical COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials DOI Creative Commons

Jinlv Qin,

Guizuo Wang,

Dong Soo Han

et al.

Clinics, Journal Year: 2025, Volume and Issue: 80, P. 100638 - 100638

Published: Jan. 1, 2025

Language: Английский

Citations

0
Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials DOI

Jinlv Qin,

Guizuo Wang,

Dong Han

et al.

Stem Cell Reviews and Reports, Journal Year: 2024, Volume and Issue: 20(4), P. 931 - 937

Published: March 1, 2024

Language: Английский

Citations

3
Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials DOI Creative Commons

Jinlv Qin,

Guizuo Wang,

Dong Han

et al.

Global Heart, Journal Year: 2023, Volume and Issue: 18(1), P. 58 - 58

Published: Oct. 26, 2023

Background: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). Methods: A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment PH macitentan, compared placebo or blank, were reviewed. Studies pooled weighted mean differences (WMDs) risk ratios (RRs), 95% confidence intervals (CIs). Results: Six RCTs (enrolling 1,003 participants) met inclusion criteria. Macitentan showed significant effects 6-min walk distance (6MWD) (WMD 12.06 m, CI 2.12 21.99 m), vascular resistance (PVR) –186.51 dyn·s/cm–5, –232.72 –140.29 dyn·s/cm–5), artery pressure (mPAP) –3.20 mmHg, –5.93 –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) –232.47 ng/L, wCI –318.22 –146.72 ng/L), cardiac index 0.39 L/min/m2, 0.20 0.58 L/min/m2). Conclusion: significantly improved 6MWD, PVR, mPAP, NT-proBNP, PH. should be further validated

Language: Английский

Citations

2